Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder

Original research
par
Brothers, Thomas D. et al

Date de publication

2022

Géographie

Canada

Langue de la ressource

English

Texte disponible en version intégrale

Oui

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

We aimed to assess the uptake of slow-release oral morphine (SROM) as second-line OAT among medically ill, hospitalised patients who declined buprenorphine and methadone.

Constatations/points à retenir

The ability to offer SROM (in addition to buprenorphine or methadone) increased rates of OAT initiation among hospitalised patients. Increasing access to SROM would help narrow the opioid use disorder treatment gap of unmet need.

La conception ou méthodologie de recherche

Hospitalised patients with untreated moderate-to-severe opioid use disorder referred to an inpatient addiction medicine consultation service, between June 2018 and September 2019, in Nova Scotia, Canada (n=34)

Mots clés

About PWUD
Outcomes
Chronic pain
Substitution/OAT
Hospitals